Hologic (NASDAQ:HOLX) Releases FY 2025 Earnings Guidance

Hologic (NASDAQ:HOLX) issued an update on its FY 2025 earnings guidance on Monday morning. The company provided earnings per share guidance of 4.250-4.350 for the period, compared to the consensus earnings per share estimate of 4.070. The company issued revenue guidance of $4.2 billion-$4.2 billion, compared to the consensus revenue estimate of $4.0 billion. Hologic also updated its FY25 guidance to $4.25-4.35 EPS.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on HOLX. Needham & Company LLC restated a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research report on Tuesday, October 15th. Leerink Partners cut their price target on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. StockNews.com cut shares of Hologic from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 27th. JPMorgan Chase & Co. lifted their target price on shares of Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research report on Tuesday. Finally, Raymond James boosted their target price on shares of Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a research note on Tuesday. Five investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, Hologic has a consensus rating of “Moderate Buy” and a consensus target price of $89.25.

Hologic Trading Up 0.8 %

Hologic stock traded up $0.61 during trading on Wednesday, reaching $79.41. 903,970 shares of the company were exchanged, compared to its average volume of 1,588,025. Hologic has a 52-week low of $66.93 and a 52-week high of $84.67. The company has a market capitalization of $18.44 billion, a P/E ratio of 26.80, a PEG ratio of 2.98 and a beta of 0.98. The stock’s 50 day simple moving average is $81.05 and its two-hundred day simple moving average is $78.11. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.32.

Hologic (NASDAQ:HOLX) last issued its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting analysts’ consensus estimates of $1.01. The company had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. Hologic had a net margin of 17.59% and a return on equity of 19.53%. Hologic’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.89 earnings per share. On average, equities research analysts expect that Hologic will post 4.09 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.